REGN241108C860000
- 2.85
- -1.40-32.94%
Regeneron Pharmaceuticals Newsroom
Regeneron Pharma Is Maintained at Outperform by Oppenheimer
Regeneron Pharmaceuticals Analyst Ratings
Oppenheimer Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,000
Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Announces Target Price $1,126
Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,110
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,195
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
TD Cowen Reaffirms Their Buy Rating on Regeneron (REGN)
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $800 to $1,195
Regeneron Pharma Price Target Cut to $1126.00/Share From $1137.00 by Truist Securities
Regeneron Pharma Is Maintained at Buy by Truist Securities
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $800 to $1,300
Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $1,110 From $1,135
Regeneron Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,242
Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $1,135 From $1,210, Maintains Outperform Rating
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,080
Regeneron Pharmaceuticals Analyst Ratings
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,260
Evercore Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,175